FINWIRES · TerminalLIVE
FINWIRES

Life360 Posts 'Good' Q1 Result, Jefferies Says

By

Life360 (ASX:360) posted a "good" first-quarter result, driven by core subscription revenue, Jefferies said in a note.

The technology company reported Tuesday first-quarter earnings of $0.03 per share, down from $0.05 a year earlier.

Meanwhile, revenue for the three months ended March 31 was $143.1 million, with subscription strength and a step-up in advertising revenue after the Nativo platform acquisition, compared with $103.6 million a year earlier.

Life360 raised its 2026 guidance, now expecting consolidated revenue of between $650 million and $685 million, up from the previous range of $640 million to $680 million, and adjusted earnings before interest, taxes, depreciation, and amortization of $130 million to $140 million, compared with prior guidance of $128 million to $138 million.

Jefferies maintained its buy rating and AU$31 price target on Life360.

Life360 shares fell 11% in afternoon trade Tuesday.

Related Articles

Asia

Shenzhen LDROBOT Soars 103% in Hong Kong Trading Debut

Shenzhen LDROBOT's (HKG:1236) shares opened 102.9% above their initial public offering price in a stellar Hong Kong debut on Monday morning.The Chinese robotics company opened at HK$53.50 per share, well above the offer price of HK$26.36.

HKG:1236
Asia

Concord Healthcare to Issue HK$68 Million Convertible Bonds to CSPC Pharma Unit

Concord Healthcare (HKG:2453) agreed to issue HK$68 million of convertible bonds to a unit of CSPC Pharmaceutical (HKG:1093), according to a Monday Hong Kong bourse filing.The oncology healthcare service provider said Dragon Merit will subscribe to the 2% convertible bonds due in April 2027.The bonds are convertible into as many as 40 million Hong Kong-listed shares at an initial conversion price of HK$1.70 per share, representing a premium of about 14.1% to the stock's last closing price.Net proceeds of about HK$63.1 million will mainly be used to repay loans and supplement working capital.Concord Healthcare said the investment is expected to deepen cooperation with CSPC Pharmaceutical in the oncology healthcare sector.

HKG:1093HKG:2453
Asia

Alterity Therapeutics Says Peer-Reviewed Study Validates its Approach to Multiple System Atrophy; Shares Fall 9%

Alterity Therapeutics (ASX:ATH) said findings of a study published in the NeuroImage journal support quantitative susceptibility mapping as an objective imaging biomarker to facilitate the earlier diagnosis of multiple system atrophy (MSA), according to a Monday filing with the Australian bourse.Alterity is advancing its ATH434 lead candidate into a phase three program for multiple system atrophy, a neurodegenerative disease that leads to the failure of the autonomic nervous system and impaired movement.The company said it used quantitative susceptibility mapping in a phase two trial in which ATH434 helped improve diagnostic accuracy and provided "objective evidence of target engagement."The peer-reviewed publication validates the company's approach and "reinforces the role of [quantitative susceptibility mapping] as a biomarker for iron-modulating therapies in MSA," Alterity CEO David Stamler said.The company's shares fell 9% in recent Monday trade.

ASX:ATH